Tripodi A S, Contos S, Germogli R
Institute of Pharmacology II, University of Pavia, Italy.
Arzneimittelforschung. 1993 Aug;43(8):877-80.
In this study we investigated the anticholelithogenic and choleretic activities and the general pharmacological action of taurohyodeoxycholic acid (THDCA, Io, Praxis, CAS 2958-04-5), a new biliary acid advocated for use as anticholelithogenic agent. THDCA had no significant activity on the CNS (spontaneous locomotor activity, body temperature, coordinated movement, respiration); it also had no significant anticonvulsant or central anticholinergic actions. With regard to the action on the cardiovascular system, THDCA administration did not give rise to significant changes in blood pressure or ECG. Investigation of its action on the gastrointestinal system revealed no significant changes in the intestinal transport of charcoal after treatment. However, biliary flow and biliary solids content were increased by THDCA intraduodenal doses of 300 mg/kg b.w. In mice fed with lithogenic diet THDCA administration (230 and 450 mg/kg b.w. for 8 weeks) significantly decreased gallstone and steatosis incidence.
在本研究中，我们调查了牛磺猪去氧胆酸（THDCA，Io，Praxis，CAS 2958-04-5）的抗胆石形成和利胆活性以及一般药理作用，THDCA是一种被提倡用作抗胆石形成剂的新型胆汁酸。THDCA对中枢神经系统（自发运动活性、体温、协调运动、呼吸）无显著活性；它也没有显著的抗惊厥或中枢抗胆碱能作用。关于对心血管系统的作用，给予THDCA后血压或心电图无显著变化。对其对胃肠道系统作用的研究表明，治疗后木炭在肠道内的转运无显著变化。然而，十二指肠内给予300mg/kg体重的THDCA可增加胆汁流量和胆汁固体含量。在喂食致石饮食的小鼠中，给予THDCA（230和450mg/kg体重，持续8周）可显著降低胆结石和脂肪变性的发生率。
